{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T14:04:46Z","timestamp":1794233086822,"version":"4.9.0"},"reference-count":10,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":["Clin Nucl Med"],"published-print":{"date-parts":[[2022,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>A 48-year-old man, a case of metastatic insulinoma, who failed transarterial chemoembolization of liver metastases underwent multiple cycles of peptide receptor radionuclide therapy with <jats:sup>177<\/jats:sup>Lu-DOTATATE, following which a complete morphologic and metabolic response was demonstrated on <jats:sup>68<\/jats:sup>Ga-DOTATATE PET\/CT. Patient had a remarkable improvement in his quality of life as intractable hypoglycemic episodes resolved after treatment. Peptide receptor radionuclide therapy is a promising targeted radionuclide therapy in patients of metastatic insulinomas that can result in reduced tumor burden and improved quality of life, particularly those who fail the conventional treatment modalities as seen in the present case.<\/jats:p>","DOI":"10.1097\/rlu.0000000000003831","type":"journal-article","created":{"date-parts":[[2021,7,21]],"date-time":"2021-07-21T00:00:48Z","timestamp":1626825648000},"page":"e77-e78","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":2,"title":["Complete Resolution of Disease After Peptide Receptor Radionuclide Therapy in a Patient of Metastatic Insulinoma"],"prefix":"10.1097","volume":"47","author":[{"given":"Priyanka","family":"Verma","sequence":"first","affiliation":[{"name":"Radiation Medicine Centre, Bhabha Atomic Research Centre"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaurav","family":"Malhotra","sequence":"additional","affiliation":[{"name":"Radiation Medicine Centre, Bhabha Atomic Research Centre"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manjunath H.","family":"Dodamani","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, King Edward Memorial Hospital and Seth Gordhandas Sunderdas Medical College, Mumbai, India."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anurag R.","family":"Lila","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, King Edward Memorial Hospital and Seth Gordhandas Sunderdas Medical College, Mumbai, India."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramesh V.","family":"Asopa","sequence":"additional","affiliation":[{"name":"Radiation Medicine Centre, Bhabha Atomic Research Centre"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tushar R.","family":"Bandgar","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, King Edward Memorial Hospital and Seth Gordhandas Sunderdas Medical College, Mumbai, India."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2021,7,20]]},"reference":[{"key":"bib1-20250621","first-page":"210","article-title":"Malignant insulinoma with hepatic and pulmonary metastases associated with primary hyperparathyroidism. Case report and review of the literature","volume":"1","year":"2008","journal-title":"J Med Life"},{"key":"bib2-20250621","doi-asserted-by":"crossref","first-page":"3381","DOI":"10.1210\/jc.2011-1563","article-title":"Improved control of severe hypoglycemia in patients with malignant insulinomas by peptide receptor radionuclide therapy","volume":"96","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"key":"bib3-20250621","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1007\/s11864-017-0461-5","article-title":"Treatment strategies for metastatic neuroendocrine tumors of the gastrointestinal tract","volume":"18","year":"2017","journal-title":"Curr Treat Options Oncol"},{"key":"bib4-20250621","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1111\/cen.13528","article-title":"Multidisciplinary management of refractory insulinomas","volume":"88","year":"2018","journal-title":"Clin Endocrinol (Oxf)"},{"key":"bib5-20250621","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1097\/RLU.0000000000001023","article-title":"Metastatic insulinoma pancreatic neuroendocrine tumor treated with 177Lu-DOTATATE induction and maintenance peptide receptor radionuclide therapy: a suggested protocol","volume":"41","year":"2016","journal-title":"Clin Nucl Med"},{"key":"bib6-20250621","doi-asserted-by":"crossref","first-page":"126","DOI":"10.2174\/1874471012666190201164132","article-title":"Peptide receptor radionuclide therapy for pancreatic neuroendocrine tumours","volume":"12","year":"2019","journal-title":"Curr Radiopharm"},{"key":"bib7-20250621","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.hoc.2015.09.009","article-title":"Peptide receptor radionuclide therapy in the treatment of neuroendocrine tumors","volume":"30","year":"2016","journal-title":"Hematol Oncol Clin North Am"},{"key":"bib8-20250621","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1007\/s40618-018-0911-3","article-title":"Peptide receptor radionuclide therapy with 177Lu-DOTA-TATE as a promising treatment of malignant insulinoma: a series of case reports and literature review","volume":"42","year":"2019","journal-title":"J Endocrinol Invest"},{"key":"bib9-20250621","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1097\/RLU.0000000000000962","article-title":"Resolution of hyperreninemia, secondary hyperaldosteronism, and hypokalemia with 177Lu-DOTATATE induction and maintenance peptide receptor radionuclide therapy in a patient with pancreatic neuroendocrine tumor","volume":"40","year":"2015","journal-title":"Clin Nucl Med"},{"key":"bib10-20250621","first-page":"e330","article-title":"Long-term effect of 177Lu-DOTATATE on severe and refractory hypoglycemia associated with malignant insulinoma","volume":"26","year":"2019","journal-title":"AACE Clin Case Rep"}],"container-title":["Clinical Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/RLU.0000000000003831","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,21]],"date-time":"2025-06-21T20:06:40Z","timestamp":1750536400000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/RLU.0000000000003831"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,20]]},"references-count":10,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.1097\/rlu.0000000000003831","relation":{},"ISSN":["1536-0229","0363-9762"],"issn-type":[{"value":"1536-0229","type":"electronic"},{"value":"0363-9762","type":"print"}],"subject":[],"published":{"date-parts":[[2021,7,20]]}}}